WE
WE HAVE
WE HAVE TO HUNKER DOWN AND GET READY FOR THE WINTER.
>>
>>
>> JOHN
>> JOHN LAURENCE FOX 61 NEWS AND
TO TALK MORE ABOUT RUN DESERT
FEAR AND OTHER TREATMENTS, WE
ARE JOINED BY DR. WHITE FROM
THE UCONN SCHOOL OF PHARMACY
THIS MORNING.
THIS MORNING. >>
>>
>> DOCTOR
>> DOCTOR DR. WHITE, THANK YOU SO
MUCH FOR JOINING.
HI.
HI.
HI. SO
HI. SO CAN YOU JUST TELL US HOW BIG
OF A GAME CHANGER IS THIS ROOM
DOES OF YOUR NEWS WHAT EXACTLY
DOES IT MEAN AND WHAT DID
TREATMENT LOOK LIKE BEFORE THIS
APPROVAL AND WHAT'S IT GOING TO
LOOK LIKE NOW?
>>
>>
>> YES,
>> YES, THIS IS THE FIRST FDA
APPROVED THERAPY AND FOR PEOPLE
THAT ARE HOSPITALIZED THAT NEED
SUPPLEMENTAL OXYGEN, IT'S A
GOOD OPTION.
GOOD OPTION. SO PEOPLE WHO WOULD BE IN
THE HOSPITAL FOR UP TO 15 DAYS
WERE GETTING OUT OF
THE HOSPITAL IN AROUND 10 DAYS.
SO I MEAN THAT'S VERY
SIGNIFICANT WHEN YOU THINK
ABOUT THE RISK THAT THE HEALTH
SYSTEM CAN HAVE OF HOSPITALS
BEING OVERWHELMED WITH
PATIENTS.
PATIENTS.
PATIENTS. SO IF YOU CAN MOVE THEM THROUGH
BY GIVING THEM THIS ANTIVIRAL
COMPOUND, THEN YOU HAVE MORE
CAPACITY FOR PATIENTS WHO HAVE
COPE AT 19 WHO ARE COMING IN OR
EVEN PATIENTS WHO DON'T HAVE AT
19.
19.
19. THEY
19. THEY BROKE THEIR LEG.
SOMETHING ELSE HAS HAPPENED TO
THEM AND THEY ALSO NEED TO BE
ABLE TO BE IN THE HOSPITAL.
THE ONE THING THAT IT DOESN'T
DO IS IT DOESN'T PROLONG
PEOPLE'S SURVIVAL.
PEOPLE'S SURVIVAL. BUT YOU KNOW, WE DO HAVE A
THERAPY THAT DOES FOR
THE SICKEST PATIENTS AND THOSE
ARE STEROIDS.
ARE STEROIDS. AND THE REALLY GOOD NEWS IS
THAT UP TO A COUPLE OF MONTHS
AGO WE ONLY THOUGHT THAT IT WAS
DEX A METHOD ZONES THAT ONLY
ONE OF THOSE CORTICOSTEROIDS
THAT WAS PROVIDING BENEFIT.
BUT WE NOW KNOW THAT YOU CAN
USE A WIDE VARIETY OF
CORTICOSTEROIDS AND THAT'S
REALLY, REALLY GOOD TRYING TO
PREVENT A SHORTAGE THAT WE
COULD HAVE WITH THAT PRODUCT.
>>
>>
>> AND
>> AND TALKING ABOUT STEROIDS,
THERE WAS RECENTLY A BUNCH OF
SURVEYS THAT WERE COMPLETED AS
YOU MENTIONED SAYING THAT THEY
CAN TREAT CRITICALLY ILL
PATIENTS AND CUT THEIR RISK OF
DYING.
DYING.
DYING. CAN YOU TALK ABOUT THAT
TREATMENT?
TREATMENT? WHAT THAT MEANS?
>>
>>
>> YES.
YES.
YES. SO
YES. SO YOU KNOW, THE FIRST TRY WAS
THE RECOVERY TRIAL AND THEY
WERE ABLE TO SHOW REDUCTIONS OF
AROUND 20 PERCENT WHEN YOU PUT
ALL THE STUDIES IN TOGETHER.
WE'RE LOOKING AT MORTALITY
REDUCTIONS BETWEEN 20 AND 30
PERCENT.
PERCENT.
PERCENT. SO WE'RE IN A MUCH BETTER PLACE
THAN WE WERE IN MARCH, APRIL,
MAY.
MAY.
MAY. IN
MAY. IN TERMS OF SOMEBODY WHO IS
SEVERELY ILL AND THE RISK OF
THAT PERSON DYING,
UNFORTUNATELY THE HEDGES WE
HAVE MANY, MANY MORE PEOPLE
ACROSS THE COUNTRY WHO ARE NOW
GETTING INFECTED AND BECAUSE
THAT INFECTION RATE IS SO MUCH
HIGHER, THE NUMBER OF EXPECTED
DEATHS HAS REALLY NOT DROPPED
TO THE LEVEL THAT WE WOULD HAVE
LIKED AND THE TREND IS UPWARDS
AND WE DON'T KNOW HOW HOW HIGH
IT'S GOING TO GO BUT IT LOOKS
LIKE IT WILL HIT NEW HIGHS
ALONG WITH WHAT'S GOING ON WITH
FLU SEASON WHICH IS GOING TO
REALLY, REALLY COMPLICATE
TREATMENT IN THE UNITED STATES.
>>
>>
>> RIGHT.
RIGHT.
RIGHT. AND GOING BACK TO THIS NEWS
ROOM AS DESERT VIEWER, YOU KNOW
APPROVAL IS ONE THING BUT
DISTRIBUTION IS REALLY, REALLY
IMPORTANT AS WELL.
CAN YOU TALK ABOUT WHAT THAT
SITUATION LOOKS LIKE?
>>
>>
>> YES.
YES.
YES. THE
YES. THE THINGS IN THE UNITED STATES
WERE A LITTLE HAIRY OVER
THE SUMMER.
THE SUMMER. RIGHT NOW THINGS LOOK PRETTY
GOOD IN TERMS OF SUPPLY BUT
THERE WERE ISSUES OVER IN
EUROPE AND THEY JUST SENT
SEVERAL HUNDRED THOUSAND DOSES
OVER OVER THERE.
AND AS THESE CASES START TO
RAMP UP AND THE PEOPLE START
COMING INTO THE HOSPITAL, ONE
OF THE BIG RISKS THAT WE END UP
RUNNING INTO IS THAT WE WILL
HAVE AN INCREASED RISK OF
SHORTAGE AND YOU KNOW, IT ISN'T
JUST A SHORTAGE OF REM DEATH
SEVERE WHEN WE START SEEING
THESE NEW SURGES IN CASES IT'S
ALSO THINGS LIKE SEDATIVES,
THINGS THAT YOU WOULD NEED TO
GIVE PEOPLE IN ORDER TO BE ABLE
TO PUT THEM ON MECHANICAL
VENTILATION, PARALYTIC DRUGS SO
THAT YOU CAN PUT THEM ON
MECHANICAL VENTILATION,
MECHANICAL VENTILATION, INTRAVENOUS MULTIVITAMINS OR
THINGS THAT YOU WOULD NEED TO
GIVE THEM PARENTAL NUTRITION
ARE NOW IN SHORT SUPPLY
ANTICOAGULANT DRUGS TO TRY TO
TREAT THE BLOOD CLOTTING THAT
CAN HAPPEN PEOPLE WHO HAVE
COAUTHORED 19 AND EVEN
SOMETHING LIKE ALBUTEROL.
SO YOU HAVE PEOPLE THAT ARE
COMIN IN WITH THESE
RESPIRATORY PROBLEMS AND YOU'RE
TRYING TO GIVE THEM THESE BETA
2 AGONISTS IN ORDER TO HELP
THEM BE ABLE TO BREATHE BETTER.
THOSE PRODUCTS ARE ALSO
STARTING TO GO IN SHORT SUPPLY.
SO ONE OF THE BIG RISKS THAT WE
HAD IS THAT WE DIDN'T SEE
THINGS COOL OFF LIKE IT DID IN
IN WESTERN EUROPE WHERE THEY
HAD THEIR INITIAL SURGE AND
THEY HAD THE ENTIRE SUMMER TO
BE ABLE TO RESTOCK OUR CASES
ENDED UP KEEPING HIGH SO WE
KEPT USING THOSE PRODUCTS.
SO WE DON'T HAVE AS MUCH OF A
RESERVE OF THOSE PRODUCTS.
SO IT'S REALLY IMPORTANT TO TRY
TO SLOW THE SPREAD AS MUCH AS
WE CAN.
WE CAN.
WE CAN. >>
>>
>> AND
>> AND AS
>> AND AS WE TALK ABOUT ALL THIS
TREATMENT, WOULD YOU SAY THAT
THE SITUATION HERE IN THE U.S.
IN TERMS OF TREATMENT WOULD YOU
SAY IT'S HOPEFUL RIGHT NOW?
WHAT DO YOU DESCRIBE THAT AS?
>>
>>
>> I
>> I WOULD SAY IT'S DEFINITELY
HOPEFUL.
HOPEFUL.
HOPEFUL. YOU KNOW, WE HAVE TWO NEW
EXPERIMENTAL THERAPIES THAT
LOOK PROMISING EITHER
MONOCLONAL OR POLY COLONIAL
ANTIBODY THERAPY.
ANTIBODY THERAPY. SO OVER THE SUMMER PEOPLE WERE
TALKING ABOUT THIS CONVALESCENT
PLASMA TREATMENT.
PLASMA TREATMENT. BUT ONE OF THE PROBLEMS IS YOU
DON'T KNOW WHETHER THE PLASMA
THAT YOU'RE GETTING FROM
SOMEBODY ELSE IS THE BEST
QUALITY PLASMA OR NOT.
SO WHAT THEY'VE DONE NOW IS
THEY TAKEN SOME OF THE BEST
QUALITY ANTIBODIES AND THEY'VE
GENETICALLY REPLICATED THEM.
SO EVERYONE WOULD GET A SIMILAR
OVERALL EFFECT.
OVERALL EFFECT. AND THAT'S VERY PROMISING.
BUT YOU KNOW, THOSE STUDIES
AREN'T OUT IN IT'S FINALITY.
SO THEY KNOW THAT IT CAN CLEAR
THE VIRUS WELL BUT THEY DON'T
KNOW WHETHER THAT MEANS PEOPLE
WOULD LIVE LONGER, WHETHER THAT
MEANS PEOPLE WOULD END UP NOT
BEING HOSPITALIZED.
BEING HOSPITALIZED. SO THERE'S STILL A LOT OF WORK
TO DO.
TO DO.
TO DO. AND EVEN IF THAT COMES OUT,
IT'S GOING TO BE IN VERY, VERY
LIMITED SUPPLY AS IT'S NOT
SOMETHING THAT'S GOING TO BE
ABLE TO ROLL OUT THROUGHOUT
THE ENTIRE COUNTRY RIGHT AWAY.
YEAH.
YEAH.
YEAH. >>
>>
>> WE'RE
>> WE'RE KEEPING OUR FINGERS
CROSSED ON THAT FRONT.
SWITCHING GEARS NOW, YOU DID
SEND US A LINK TO AN ARTICLE
ABOUT WHY THE FDA IS WARNING
PREGNANT WOMEN NOT TO USE
OVER-THE-COUNTER PAIN
OVER-THE-COUNTER PAIN RELIEVERS.
RELIEVERS. CAN YOU TALK ABOUT THAT
ARTICLE?
ARTICLE?
ARTICLE? YEAH.
YEAH.
YEAH. SO
YEAH. SO WOMEN WHO ARE READ PAST
THEIR 20TH WEEK THEY BEGAN TO
NOTICE THAT WHEN THEY WERE
USING NON STEROIDAL ANTI
INFLAMMATORY DRUGS IF THEY WERE
JUST HAPPENING TO GET AN
ULTRASOUND THEY WERE SEEING
LOWER THAN NORMAL
CONCENTRATIONS OF AMNIOTIC
FLUID.
FLUID.
FLUID. SO
FLUID. SO THAT'S THAT FLUID THAT
SURROUNDS THE BABY AND THAT
AMNIOTIC SAC.
AMNIOTIC SAC. AND WHAT HAPPENS IS THAT AFTER
20 WEEKS OF GESTATION IT'S
ACTUALLY THE BABY'S KIDNEYS
THAT ARE PRODUCING THAT
PROTECTIVE FLUID ANNOUNCER AT
AN ANTI INFLAMMATORY DRUGS WERE
COMPROMISING THE INFANT'S
ABILITY TO MAKE THAT FLUID AND
THEN WHEN THEY STOPPED TAKING
THE NON STEROIDAL THEY SAW
THE LEVELS COME BACK UP.
AND THEN IN SOME CASES THEY PUT
BACK ON NON STEROIDAL TO SEE
WHAT WOULD HAPPEN.
AND BOTH LEVELS WENT DOWN SO
DOWN STEROID WHAT WE'RE TALKING
ABOUT IS EVEN COMMON
OVER-THE-COUNTER THINGS LIKE
IBUPROFEN, NAPROXEN AND ASPIRIN
,THINGS LIKE ALEVE OR ADVIL
ARE SOME OF THOSE ARE SOME OF
THOSE THINGS THAT IF YOU WANT
TO USE THEM AFTER 20 WEEKS OF
PREGNANCY MAKE SURE YOU TALK TO
YOUR OBSTETRICIAN.
YOUR OBSTETRICIAN. THEY MAY WANT TO DO THOSE
ULTRASOUNDS TO MAKE SURE THAT
WITH YOUR BABY THAT IT'S NOT
DOING ANYTHING TO COMPROMISE
THEIR KIDNEY FUNCTION.